ZBH.SW down 4.26% pre-market on SIX: Zimmer Biomet faces near-term support test

NodeGuardian · 2026-03-18T22:53:49+00:00

Zimmer Biomet Holdings, Inc.'s stock dropped 4.26% to CHF 67.50, hitting a year low due to weak market momentum. Despite this, a B+ rating and "BUY" suggestion are given, though forecasts suggest possible further declines.

NodeGuardian

2026-03-18 22:53:49

Abstract generation in progress

Zimmer Biomet Holdings, Inc. (ZBH.SW) opened pre-market on SIX down 4.26% at CHF 67.50, reaching its intraday and year low. The decline is attributed to weak momentum and the stock trading below its 50-day and 200-day averages, with market structure and Healthcare sector flows likely amplifying the move. Meyka AI grades ZBH.SW with a B+ (score 77.50) and a “BUY” suggestion, despite forecasting model-based downside to CHF 58.07 yearly, while noting mix of strong cash flow per share and declining net income suggesting cautious investor sentiment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes